The PIX306 trial is a randomized, multicenter trial comparing pixantrone combined with rituximab versus gemcitabine combined with rituximab in 312 patients with aggressive B-cell non-Hodgkin lymphoma who had relapsed after therapy with CHOP-R or an equivalent regimen and were ineligible for stem cell transplant.
The primary endpoint was progression-free survival while overall survival, complete response rate, overall response rate, and safety were secondary endpoints.
Pixantrone is a cytotoxic medicine that interferes with DNA replication causing cancer cells to stop dividing and eventually die.
Servier, governed by a non-profit foundation, has an international presence in 148 countries and employs 21,000 people worldwide.
Entirely independent, the group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development in five areas: cardiovascular, immune-inflammatory, neuropsychiatric, cancers, and diabetes.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers. The company has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study